Efficacy of pars plana vitrectomy (PPV) for visually significant vitreous opacities.
DOI:
https://doi.org/10.29309/TPMJ/2022.29.02.6720Keywords:
Floaters, Pars Plana Vitrectomy, Vitreous OpacitiesAbstract
Objective: To study the efficacy of pars plana vitrectomy (PPV) for visually significant vitreous opacities in improving visual function and quality of life. Study Design: Interventional study. Setting: Department of Vitreoretinal Clinic of Ophthalmology, Nishtar University Hospital Multan. Period: May 2017 to August 2019. Material & Methods: A total of 50 patients of both genders, aged 35 to 65 years having lenticular status (Phakic or pseudophakic patients) and planned for PPV were enrolled for this study. All patients were examined on slit lamp bio microscope. Dilated fundus examination was performed with indirect ophthalmoscope using scleral indentation. Intraocular pressure was measured pre and postoperatively with Goldmann’s applanation tonometer under topical anaesthesia. Diagnosis was made on through clinical examination. All patients underwent 23 gauge PPV with or without silicon oil with endo laser. Best spectacle corrected visual acuity was recorded with help of Snellen chart. Results: There were 50 eyes of 50 patients in two groups, 40 phakic eyes (80%) and 10 pseudophakic eyes (20%) that underwent 3 PPV for visually significant opacities. There were 38 (76.0%) male and 12 (24.0%) female patients. Thirty four (68.0%) out of 50 patients showed improved best spectacle corrected visual acuity (BSCVA) and visual function while 18% had BCVA 6/24 – 6/18. Forty three (86.0%) patients reported quality of life and psychological feel improvement. Conclusion: Pars plana vitrectomy is a safe, effective and viable option for annoying vitreous floaters. There are risks of retinal breaks, rhegmatogenous retinal detachment and cataract. Surgeon must be ready for prompt handling of patient.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 The Professional Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.